Retrospective analysis of inotuzumab-associated hepatotoxicity in adult patients with B-cell acute lymphoblastic leukemia: Expanding the Spectrum of calicheamicin syndrome
Journal of Oncology Pharmacy Practice
Published online on April 10, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundInotuzumab ozogamicin (InO), a CD22-directed antibody–drug conjugate, is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but hepatotoxicity remains a recognized adverse effect, most commonly sinusoidal ...
BackgroundInotuzumab ozogamicin (InO), a CD22-directed antibody–drug conjugate, is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but hepatotoxicity remains a recognized adverse effect, most commonly sinusoidal ...